Compare Stocks: QURE, EXEL, BMRN, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.64B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.69B	0.44	2.68 million shs	1.49 million shs
MDGL Madrigal Pharmaceuticals	$533.76 -1.8%	$526.96	$393.61 ▼ $615.00	$12.56B	-1.01	321,180 shs	268,664 shs
QURE uniQure	$48.72 -1.7%	$44.44	$8.73 ▼ $71.50	$3.44B	0.92	1.11 million shs	843,555 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
MDGL Madrigal Pharmaceuticals	-1.83%	+3.29%	-2.40%	+7.34%	+25.57%
QURE uniQure	-1.69%	+0.72%	+21.59%	+70.77%	+209.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.64B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.69B	0.44	2.68 million shs	1.49 million shs
MDGL Madrigal Pharmaceuticals	$533.76 -1.8%	$526.96	$393.61 ▼ $615.00	$12.56B	-1.01	321,180 shs	268,664 shs
QURE uniQure	$48.72 -1.7%	$44.44	$8.73 ▼ $71.50	$3.44B	0.92	1.11 million shs	843,555 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
MDGL Madrigal Pharmaceuticals	-1.83%	+3.29%	-2.40%	+7.34%	+25.57%
QURE uniQure	-1.69%	+0.72%	+21.59%	+70.77%	+209.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.79	37.30% Upside
EXEL Exelixis	2.30	Hold	$50.07	-8.05% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.64	31.08% Upside
QURE uniQure	2.71	Moderate Buy	$65.00	33.42% Upside

Current Analyst Ratings Breakdown

Latest QURE, EXEL, BMRN, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/10/2026	BMRN BioMarin Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$111.00 ➝ $114.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.89	$2.83 per share	22.88	$32.66 per share	1.98
EXEL Exelixis	$2.32B	5.82	$2.98 per share	18.25	$7.44 per share	7.32
MDGL Madrigal Pharmaceuticals	$958.40M	12.87	N/A	N/A	$22.67 per share	23.54
QURE uniQure	$18.67M	180.99	N/A	N/A	$4.67 per share	10.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	174.78	11.98	0.47	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.12	14.68	1.64	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	96.17	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest QURE, EXEL, BMRN, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
MDGL Madrigal Pharmaceuticals	98.50%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
MDGL Madrigal Pharmaceuticals	17.60%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable
QURE uniQure	500	69.37 million	66.14 million	Optionable

QURE, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?

August 28 at 12:35 PM | zacks.com

uniQure (NASDAQ:QURE) Stock Price Up 8.7% - What's Next?

August 25, 2026 | marketbeat.com

Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE

August 19, 2026 | marketbeat.com

uniQure Charts Accelerated Path With AMT‑130

August 16, 2026 | tipranks.com

uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating

August 15, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE

August 10, 2026 | marketbeat.com

Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE

August 10, 2026 | marketbeat.com

uniQure (QURE) Q2 2026 Earnings Call Transcript

August 7, 2026 | finance.yahoo.com

uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages

August 7, 2026 | marketbeat.com

Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE

August 3, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for uniQure Q3 Earnings

August 3, 2026 | marketbeat.com

uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen

August 1, 2026 | marketbeat.com

uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course

July 31, 2026 | seekingalpha.com

Barclays Keeps Their Buy Rating on uniQure (QURE)

July 31, 2026 | theglobeandmail.com

UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma

July 31, 2026 | biospace.comB

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

July 30, 2026 | zacks.com

Wells Fargo & Company Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price

July 30, 2026 | marketbeat.com

uniQure N.V. (QURE) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

UniQure outlines AMT-130 BLA this quarter, supported by cash runway into 2030

July 30, 2026 | seekingalpha.com

AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says

July 30, 2026 | finance.yahoo.com

Stempoint Capital LP Has $1.28 Million Stock Position in uniQure N.V. $QURE

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.67 -0.62 (-0.95%)

As of 08/28/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.45 -0.81 (-1.47%)

As of 08/28/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$533.76 -9.93 (-1.83%)

As of 08/28/2026 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

uniQure NASDAQ:QURE

$48.72 -0.84 (-1.69%)

As of 08/28/2026 04:00 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, EXEL, BMRN, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, EXEL, BMRN, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, EXEL, BMRN, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, EXEL, BMRN, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, EXEL, BMRN, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, EXEL, BMRN, and MDGL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Madrigal Pharmaceuticals NASDAQ:MDGL

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools